Side-effects in women treated with adjuvant endocrine therapy for breast cancer
Publication date
2025-04
Authors
Rademaker, L. M.
Gal, Roxanne
May, Anne M
Batenburg, Marilot C.T.
van der Leij, Femke
Bijlsma, Rhodé M
Verkooijen, Helena M
Doeksen, A.
Ernst, M. F.
Evers, D. J.
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by
Abstract
Many women with breast cancer prematurely discontinue adjuvant endocrine therapy, leading to increased mortality. We performed a cross-sectional survey (n = 456) within the Dutch UMBRELLA-cohort to gain insight into the prevalence of side-effects and its association with premature discontinuation. Almost all current endocrine therapy users experienced side-effects (92.7 %), most frequent were vasomotor- and musculoskeletal symptoms. The most reported reason for premature discontinuation was side-effects (88.1 %). Former treatment with chemotherapy was associated with more reported side-effects (97.2 % vs 82.5 %, ORadj 6.31), but less premature discontinuation of endocrine therapy (18.6 % vs 28.6 %, p-value 0.016).
Keywords
Adjuvant therapy, Discontinuation of therapy, Endocrine therapy, ER positive, Side-effects, Surgery, Oncology, Cancer Research
Citation
Rademaker, L M, Gal, R, May, A M, Batenburg, M C T, van der Leij, F, Bijlsma, R M, Verkooijen, H M, Doeksen, A, Ernst, M F, Evers, D J, van der Pol, C C & Monninkhof, E M 2025, 'Side-effects in women treated with adjuvant endocrine therapy for breast cancer', Breast, vol. 80, 104416. https://doi.org/10.1016/j.breast.2025.104416